Drugs / ICP-B794
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07136558 | Aug 2025 → Jun 2029 expected | cancer | Beijing InnoCare Pharma Tech Co., Ltd. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-04-20 | Beijing InnoCare Pharma Tech Co., Ltd. | Results 新型B7-H3 ADC ICP-B794 临床前数据亮相2026 AACR，展示优异的抗肿瘤活性和安全性 innocarepharma.com ↗ |
| 2025-07-03 | Beijing InnoCare Pharma Tech Co., Ltd. | Regulatory 诺诚健华新型ADC创新药ICP-B794获批临床 innocarepharma.com ↗
今天宣布，公司自主研发的靶向B7-H3 的新型ADC创新药ICP-B794获国家药品监督管理局（NMPA）药品审评中心（CDE）批准开展临床研究。 |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-04-20 | Beijing InnoCare Pharma Tech Co., Ltd. | 新型B7-H3 ADC ICP-B794 临床前数据亮相2026 AACR，展示优异的抗肿瘤活性和安全性 innocarepharma.com ↗ |
| 2025-07-03 | Beijing InnoCare Pharma Tech Co., Ltd. | 诺诚健华新型ADC创新药ICP-B794获批临床 innocarepharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ICP-B794 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07136558 ↗ |
| Route | Intravenous | “Intravenous administration once every 3 weeks” NCT07136558 ↗ |